New approaches for temozolomide therapy: use in newly diagnosed glioma

Details

Serval ID
serval:BIB_B8017927CC8F
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
New approaches for temozolomide therapy: use in newly diagnosed glioma
Journal
Seminars in Oncology
Author(s)
Stupp  R., Newlands  E.
ISSN
0093-7754 (Print)
Publication state
Published
Issued date
08/2001
Volume
28
Number
4 Suppl 13
Pages
19-23
Notes
Journal Article
Review --- Old month value: Aug
Abstract
Temozolomide is a novel oral alkylating agent that has been approved for the treatment of patients with refractory malignant glioma. Treatment with temozolomide is now being explored in patients with newly diagnosed malignant glioma in several ongoing clinical trials, and alternative treatment schedules are being evaluated. A schedule of continuous daily treatment with temozolomide for 6 or 7 weeks has been developed and determined to be safe, effective, and well tolerated. When temozolomide was continuously given along with a standard course of radiation therapy for 6 or 7 weeks, followed by adjuvant treatment with temozolomide, promising preliminary results were seen in patients with malignant gliomas.
Keywords
Antineoplastic Agents, Alkylating/administration & dosage/*therapeutic use Central Nervous System Neoplasms/*drug therapy/radiotherapy Chemotherapy, Adjuvant Clinical Trials Dacarbazine/administration & dosage/analogs & derivatives/*therapeutic use Drug Administration Schedule Glioma/*drug therapy/radiotherapy Humans Quality of Life
Pubmed
Web of science
Create date
28/01/2008 8:39
Last modification date
20/08/2019 15:26
Usage data